Stocks and Investing
Stocks and Investing
Wed, February 28, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Chris Shibutani Maintained (BNTX) at Hold with Decreased Target to $100 on, Feb 28th, 2024
Chris Shibutani of Goldman Sachs, Maintained "BioNTech SE" (BNTX) at Hold with Decreased Target from $113 to $100 on, Feb 28th, 2024.
Chris has made no other calls on BNTX in the last 4 months.
There are 5 other peers that have a rating on BNTX. Out of the 5 peers that are also analyzing BNTX, 1 agrees with Chris's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Korn of "Morgan Stanley" Maintained at Hold with Increased Target to $111 on, Wednesday, November 8th, 2023
These are the ratings of the 4 analyists that currently disagree with Chris
- Bill Maughan of "Canaccord Genuity" Reiterated at Strong Buy and Held Target at $171 on, Friday, February 23rd, 2024
- Etzer Darout of "BMO Capital" Initiated at Buy and Held Target at $127 on, Friday, February 23rd, 2024
- Robert Burns of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $107 on, Tuesday, January 23rd, 2024
- Jessica Fye of "JP Morgan" Downgraded from Hold to Sell and Decreased Target to $99 on, Friday, December 1st, 2023
Contributing Sources